Lord, Abbett & Co
OCUL icon

Lord, Abbett & Co’s Ocular Therapeutix OCUL Stock Holding History

Lord, Abbett & Co’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-113,000
Closed -$1.59M – 931
2015
Q3 		$1.59M Buy
+113,000
New +$2.27M ﹤0.01% 863
2015
Q2 		– Sell
-126,000
Closed -$5.29M – 965
2015
Q1 		$5.29M Buy
+126,000
New +$4.14M 0.01% 726

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Lord, Abbett & Co's OCUL Position: Q4 2015 in Review

Lord, Abbett & Co sold out of Ocular Therapeutix (OCUL) in Q4 2015, closing a stake of 113,000 shares — an estimated $1.59M sold.

Lord, Abbett & Co first reported a position in OCUL in Q1 2015 and held it in 2 quarters. The position peaked at $5.29M in Q1 2015. 71 funds tracked by Wall St. Rank hold OCUL as of Q4 2015.

  • Lord, Abbett & Co reported no remaining Ocular Therapeutix position as of Q4 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 113,000 Ocular Therapeutix shares in Q4 2015, an estimated $1.59M.
  • Lord, Abbett & Co first reported a position in Ocular Therapeutix in Q1 2015 and held it in 2 quarters.
  • Lord, Abbett & Co's Ocular Therapeutix position peaked at $5.29M in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2015.

Based on Lord, Abbett & Co's 13F filing for Q4 2015, filed 16 Feb 2016.